

New SARS-CoV-2 IgG ELISA developed in collaboration with **Actim**

We have developed a SARS-CoV-2 IgG ELISA for mass testing of recent COVID-19 infections with Actim which is a fully owned subsidiary of Medix Biochemica.

Actim ELISA SARS-CoV-2 IgG offers additional data for pandemic analysis in healthcare, pharmaceutical and research laboratories.

An evaluation study of over 600 serum samples confirmed the excellent performance of the upcoming Actim ELISA SARS-CoV-2 IgG test:

- Sensitivity=96 %
- Specificity=99 %
- PPV=90 %
- NPV=99 %
- Accuracy=98 %

The kit is supplied by Actim, so for inquiries, please visit www.actimtest.com

